Skip to main content

The clinical utility of NGS panel testing



Date: Thursday, May 23, 2024, 11:00 AM, PDT
Access to this course expires on: November 23, 2024

Learning Objectives

Attending this session will enable learners to:

  • Understand the importance of the PI3K/AKT/PTEN pathway in HR+/HER2- locally advanced and metastatic breast cancer following progression on or after endocrine therapy ± CDK4/6i
  • Identify the actionable biomarkers in the PI3K/AKT/PTEN pathway by next-generation sequencing (NGS) testing
  • Recognize the clinical advancements in HR+/HER2- locally advanced and metastatic breast cancer, including TRUQAP + fulvestrant and the CAPItello-291 study (overview, results, and adverse reactions)
  • Understand the role of the pathologists in molecular biomarker testing

Description
Hyperactivation of the PI3K/AKT/PTEN pathway is a key driver behind resistance to endocrine therapy in HR+/HER2- breast cancers.1 Activating mutations in PIK3CA and AKT1, and loss-of-function of PTEN occur in up to 50% of HR+ breast cancer cases.2 NGS panel testing provides comprehensive information on PIK3CA, AKT1, and PTEN alterations status and may indicate eligibility for treatment with TRUQAP, combined with fulvestrant in locally advanced or metastatic breast cancer (aBC/mBC) with one or more PIK3CA, AKT1, and/or PTEN alteration following progression on or after endocrine-based regimen.3

TRUQAP is an oral, pan-AKT kinase inhibitor, that in pre-clinical models targets AKT and blocks amplified signaling driven by PIK3CA, AKT1, and/or PTEN gene alterations, inhibiting tumor growth.3,4 NGS panel testing is rapidly becoming an important tool to help pathologists and other healthcare providers to make well-informed breast cancer management decisions.

This comprehensive short course aims to support pathologists in understanding the importance of the PI3K/AKT/PTEN pathway in HR+/HER2- aBC and identifying all the actionable biomarkers in this pathway via NGS panel testing.

This presentation provides an introduction to TRUQAP and a deep dive into NGS panel testing, highlighting the importance of biomarker testing and providing an overview of guideline recommendations, helping you to take a proactive approach in advocating for NGS panel testing for all patients with aBC.

The information presented represents the opinion of the presenters and is not necessarily the view of USCAP. USCAP does not endorse the products or services. The webinar is possible through a sponsorship from AstraZeneca. This activity is not available for CME.

Presenters
Fresia Pareja, MD, PhD
Pathologist, specializing in Breast Pathology,
Memorial Sloan Kettering Cancer Center

Erika P. Hamilton, MD
Director, Breast Cancer Research Program and Gynecologic Cancer Research Program,
Sarah Cannon Research Institute

Presenters were compensated for their time


IMPORTANT PRODUCT INFORMATION
Select Safety Information About TRUQAP™ (capivasertib) tablets

TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components.

Serious adverse reactions can include hyperglycemia, diarrhea, and cutaneous adverse reactions. May cause fetal harm when administered to pregnant women. Among the 355 patients who received TRUQAP in CAPItello-291, the most common (≥20%) adverse reactions, including laboratory abnormalities, were diarrhea (72%), cutaneous adverse reactions (58%), increased random glucose (57%), decreased lymphocytes (47%), decreased hemoglobin (45%), nausea and fatigue (35% each), increased fasting glucose (37%), decreased leukocytes (32%), increased triglycerides (27%), decreased neutrophils (23%), increased creatinine (22%), vomiting (21%), and stomatitis (20%).

Indication and Usage
TRUQAP in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Please see full Prescribing Information, including Patient Information for TRUQAP.

This information is intended for US Healthcare Professionals only

Register here

Click here to take the USCAP program survey

*Following disease progression on or after endocrine therapy. Advanced breast cancer is defined as locally aBC and mBC

aBC, locally advanced breast cancer; AKT, serine/threonine protein kinase; AKT1, serine/threonine protein kinase 1; CDK4/6i, cyclin‐dependent kinase 4/6 inhibitor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; NGS, next-generation sequencing; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog.

References:
  1. Li H, et al. Cancers (Basel). 2021;13(14):3517
  2. Martorana F, et al. Front Pharmacol. 2021;12:662232
  3. TRUQAP™ (capivasertib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023.
  4. Ribas R, et al. Mol Cancer Ther. 2015;14(9):2035-2048.

TRUQAP is a trademark of the AstraZeneca group of companies.
US-84203 Last Updated 4/24

Privacy NoticeThe webinar is possible through a sponsorship from AstraZeneca. This content is not available for continuing medical education. If you continue to register, you are acknowledging that your information will be shared with the company, including your name, degrees, institution, NPI number, mailing address, email address, and phone number. USCAP has no control over the use of this information and encourages you to review their privacy policies.